Androgen therapy for patients with lower‐risk myelodysplastic syndrome and significant cytopenia: a retrospective study.

The duration between androgen therapy and the time at which 90% of patients achieved the response was 8-4, 9-8, 6-3 and 19-4 months for any HI, HI-E, HI-P and HI-N, respectively (Fig). Of the 38 patients who experienced disease progression, 25 (65-8%) and 13 (34-2%) had multi- and single-lineage cytopenia before treatment, and 16 (42-1%) had shown initial HI after androgen treatment. In univariate analysis, a higher pre-treatment haemoglobin level (>90 g/l), RBC and platelet transfusion-independency, and lower revised IPSS (IPSS-R) (<=3-5) at androgen therapy were associated with higher HI rates. [Extracted from the article]

Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)